This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
A phase 3 trial found that divarasib kept disease from progressing longer than sotorasib or adagrasib in patients with non-small-cell lung cancer. The report does not say whether divarasib improved overall survival or whether it is approved.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
The finding could matter to U.S. patients and cancer-care providers if the treatment becomes available, but the report does not establish approval or a change in care.
The report does not describe regulatory decisions, publication of full trial results, or a timeline for next steps.
Whether full trial results are published
Whether regulators review divarasib for this use